Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 6/20 | 0.34 |
| ▸ | HINT1 | P49773 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | FUT6 | P51993 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6831424 | 0.91 | TYMP (0.36) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL8006782 | 0.90 | TAAR1 (0.39) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL6835155 | 0.85 | TYMP (0.36) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL6834953 | 0.85 | TYMP (0.36) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL4343188 | 0.83 | TRDMT1 (0.37) | POLB | |
| SCHEMBL17599795 | 0.83 | TAS1R3 (0.35) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL7073590 | 0.82 | POLB (0.39) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL17599876 | 0.81 | TAS1R3 (0.35) | TYMPHPGDTAAR1POLBFUT5 | |
| SCHEMBL6316021 | 0.81 | TYMP (0.39) | TYMPHPGDTAAR1POLBHINT1 | |
| SCHEMBL17599829 | 0.81 | TAS1R3 (0.34) | TYMPHPGDTAAR1POLBFUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809824-B2 | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-07 | — | — | US | disclosed |
| US-20090263405-A1 | CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2006065751-A2 | CPG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-06-22 | — | — | WO | disclosed |
| US-6762298-B2 | DEPROTECTING AN OLIGONUCLEOTIDE BY HEATING IN A FLUID, WHERE THE PHOSPHORUS ATOM IS O-PROTECTED WITH A THERMOLABILE GROUP SUCH AS (PYRROLIDIN-1-ONE-1-YL)ALKYL; SYNTHESIS OF OLIGONUCLEOTIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2004-07-13 | — | — | US | disclosed |
| US-20010044529-A1 | Thermolabile phosphorus protecting groups, associated intermediates and methods of use | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044529-A1 | Thermolabile phosphorus protecting groups, associated intermediates and methods of use | POLR2H, POLL, POLR1A | TYMP 29/4885HPGD 4358/4885TAAR1 823/4885 |
| US-20090263405-A1 | CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS | TYMP, DCTD, TET1 | TYMP 1/4885HPGD 1185/4885TAAR1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.